ADXS
Ayala Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.56
Current Price| Previous Close | $0.64 |
| Open | $0.10 |
| Day High | $0.10 |
| Day Low | $0.08 |
| Volume | 10,014 |
Stock Information
| Shares Outstanding | 42.59M |
| Revenue | $13K |
| Net Income | $-48.07M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $23.64M |
| EPS (TTM) | $-7.99 |
| Exchange | PNK |
đ Custom Metrics & Score
Score: 8/42| Debt to Equity | -0.34 |
| Current Ratio | 0.30 |
| Quick Ratio | 0.20 |
| Avg Revenue Growth | -33.21% |
| Profit Margin | -369784.62% |
| Return on Equity | 196.88% |
| Avg FCF Growth | -7.71% |
| FCF Yield | -124.73% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.57 | 0 |
| 2026-01-30 | $0.57 | 15,381 |
| 2026-01-29 | $0.56 | 49,433 |
| 2026-01-28 | $0.64 | 33,313 |
| 2026-01-27 | $0.48 | 1,188 |
| 2026-01-26 | $0.51 | 0 |
| 2026-01-23 | $0.51 | 27,586 |
| 2026-01-22 | $0.50 | 0 |
| 2026-01-21 | $0.50 | 1,273 |
| 2026-01-20 | $0.25 | 29,170 |
| 2026-01-16 | $0.46 | 11,254 |
| 2026-01-15 | $0.40 | 48,395 |
| 2026-01-14 | $0.21 | 0 |
| 2026-01-13 | $0.21 | 128 |
| 2026-01-12 | $0.21 | 0 |
| 2026-01-09 | $0.21 | 686 |
| 2026-01-08 | $0.20 | 0 |
| 2026-01-07 | $0.20 | 0 |
| 2026-01-06 | $0.20 | 729 |
| 2026-01-05 | $0.08 | 0 |
About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.
đ° Latest News
No news articles available at the moment. Check back later for updates on ADXS.
Income Statement (Annual)
Revenue
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Reconciled Cost Of Revenue | $13,000 | $602,000 | $3,506,000 |
| Cost Of Revenue | $13,000 | $602,000 | $3,506,000 |
| Total Revenue | $13,000 | $692,000 | $3,506,000 |
| Operating Revenue | $13,000 | $692,000 | $3,506,000 |
Expenses
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Interest Expense | $15,746,000 | $0 | $260,000 |
| Total Expenses | $36,279,000 | $38,195,000 | $42,724,000 |
| Net Non Operating Interest Income Expense | $-15,718,000 | $74,000 | $-260,000 |
| Interest Expense Non Operating | $15,746,000 | $0 | $260,000 |
| Operating Expense | $36,266,000 | $37,593,000 | $39,218,000 |
| General And Administrative Expense | $12,185,000 | $9,742,000 | $9,277,000 |
Income & Earnings
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Net Interest Income | $-15,718,000 | $74,000 | $-260,000 |
| Interest Income | $28,000 | $74,000 | - |
| Normalized Income | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Net Income From Continuing And Discontinued Operation | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Total Operating Income As Reported | $-36,266,000 | $-37,503,000 | $-39,218,000 |
| Net Income Common Stockholders | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Net Income | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Net Income Including Noncontrolling Interests | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Net Income Continuous Operations | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Pretax Income | $-51,984,000 | $-37,429,000 | $-39,478,000 |
| Interest Income Non Operating | $28,000 | $74,000 | - |
| Operating Income | $-36,266,000 | $-37,503,000 | $-39,218,000 |
| Gross Profit | $0 | $90,000 | $0 |
Per Share Metrics
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Diluted EPS | $-7.99 | $-13.13 | $-2.80 |
| Basic EPS | $-7.99 | $-13.13 | $-2.80 |
Other
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-35,869,000 | $-37,267,000 | $-39,050,000 |
| Reconciled Depreciation | $369,000 | $162,000 | $168,000 |
| EBITDA (Bullshit earnings) | $-35,869,000 | $-37,267,000 | $-39,050,000 |
| EBIT | $-36,238,000 | $-37,429,000 | $-39,218,000 |
| Diluted Average Shares | $6,019,063 | $2,895,130 | $14,398,905 |
| Basic Average Shares | $6,019,063 | $2,895,130 | $14,398,905 |
| Diluted NI Availto Com Stockholders | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Tax Provision | $-3,912,000 | $584,000 | $776,000 |
| Research And Development | $24,081,000 | $27,851,000 | $29,941,000 |
| Selling General And Administration | $12,185,000 | $9,742,000 | $9,277,000 |
| Other Gand A | $12,185,000 | $9,742,000 | $9,277,000 |
Balance Sheet (Annual)
Assets
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Net Tangible Assets | $-32,815,000 | $-1,099,000 | $34,158,000 |
| Total Assets | $16,579,000 | $7,769,000 | $41,127,000 |
| Total Non Current Assets | $9,051,000 | $4,581,000 | $1,387,000 |
| Other Non Current Assets | $11,000 | $206,000 | $267,000 |
| Non Current Deferred Assets | $0 | $1,953,000 | - |
| Goodwill And Other Intangible Assets | $8,398,000 | $0 | - |
| Other Intangible Assets | $3,898,000 | - | - |
| Current Assets | $7,528,000 | $3,188,000 | $39,740,000 |
| Other Current Assets | $172,000 | $5,000 | $2,636,000 |
| Restricted Cash | $330,000 | $110,000 | $122,000 |
| Prepaid Assets | $2,144,000 | $431,000 | $2,636,000 |
| Receivables | $0 | $234,000 | $0 |
| Accounts Receivable | $0 | $234,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $4,882,000 | $2,408,000 | $36,982,000 |
| Cash And Cash Equivalents | $4,882,000 | $2,408,000 | $36,982,000 |
Debt
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Net Debt | $3,259,000 | - | - |
| Total Debt | $8,316,000 | $1,751,000 | $497,000 |
| Long Term Debt And Capital Lease Obligation | $8,150,000 | $1,332,000 | $497,000 |
| Long Term Debt | $8,141,000 | - | - |
| Current Debt And Capital Lease Obligation | $166,000 | $419,000 | - |
Liabilities
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $40,996,000 | $8,868,000 | $6,969,000 |
| Total Non Current Liabilities Net Minority Interest | $15,978,000 | $2,667,000 | $497,000 |
| Derivative Product Liabilities | $6,057,000 | $0 | - |
| Tradeand Other Payables Non Current | $1,771,000 | $1,335,000 | - |
| Current Liabilities | $25,018,000 | $6,201,000 | $6,472,000 |
| Other Current Liabilities | $12,436,000 | - | - |
| Payables And Accrued Expenses | $12,416,000 | $5,782,000 | $5,322,000 |
| Payables | $6,076,000 | $4,080,000 | $3,214,000 |
| Accounts Payable | $6,076,000 | $4,080,000 | $3,214,000 |
| Current Deferred Liabilities | - | - | $1,150,000 |
| Current Deferred Taxes Liabilities | - | - | $1,150,000 |
Equity
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Common Stock Equity | $-24,417,000 | $-1,099,000 | $34,158,000 |
| Total Equity Gross Minority Interest | $-24,417,000 | $-1,099,000 | $34,158,000 |
| Stockholders Equity | $-24,417,000 | $-1,099,000 | $34,158,000 |
| Retained Earnings | $-197,226,000 | $-149,154,000 | $-111,141,000 |
Other
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Treasury Shares Number | $39,452 | - | - |
| Ordinary Shares Number | $11,857,393 | $14,820,727 | $13,956,035 |
| Share Issued | $11,857,393 | $14,820,727 | $13,956,035 |
| Tangible Book Value | $-32,815,000 | $-1,099,000 | $34,158,000 |
| Invested Capital | $-16,276,000 | $-1,099,000 | $34,158,000 |
| Working Capital | $-17,490,000 | $-3,013,000 | $33,268,000 |
| Capital Lease Obligations | $175,000 | $1,751,000 | $497,000 |
| Total Capitalization | $-16,276,000 | $-1,099,000 | $34,158,000 |
| Additional Paid In Capital | $172,797,000 | $148,052,000 | $145,160,000 |
| Capital Stock | $12,000 | $3,000 | $139,000 |
| Common Stock | $12,000 | $3,000 | $139,000 |
| Long Term Capital Lease Obligation | $9,000 | $1,332,000 | $497,000 |
| Current Capital Lease Obligation | $166,000 | $419,000 | - |
| Current Accrued Expenses | $6,340,000 | $1,702,000 | $2,108,000 |
| Goodwill | $4,500,000 | $0 | - |
| Net PPE | $642,000 | $2,422,000 | $1,120,000 |
| Accumulated Depreciation | $-812,000 | $-660,000 | $-498,000 |
| Gross PPE | $1,454,000 | $3,082,000 | $1,618,000 |
| Leases | $1,105,000 | $1,105,000 | $1,105,000 |
| Other Properties | $197,000 | $1,758,000 | $294,000 |
| Machinery Furniture Equipment | $152,000 | $219,000 | $219,000 |
| Properties | $0 | $0 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Free Cash Flow | $-29,485,000 | $-34,510,000 | $-38,361,000 |
Operating Activities
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-29,485,000 | $-34,510,000 | $-38,356,000 |
| Cash Flow From Continuing Operating Activities | $-29,485,000 | $-34,510,000 | $-38,356,000 |
| Operating Gains Losses | $5,854,000 | - | - |
Investing Activities
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Investing Cash Flow | $5,946,000 | $-2,000 | $-5,000 |
| Cash Flow From Continuing Investing Activities | $5,946,000 | $-2,000 | $-5,000 |
| Net Other Investing Changes | $4,037,000 | $-2,000 | - |
| Capital Expenditure | - | - | $-5,000 |
Financing Activities
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $20,001,000 | $512,000 | $33,229,000 |
| Financing Cash Flow | $26,001,000 | $-103,000 | $33,330,000 |
| Cash Flow From Continuing Financing Activities | $26,001,000 | $-103,000 | $33,330,000 |
| Net Common Stock Issuance | $20,001,000 | $-103,000 | $33,229,000 |
| Common Stock Issuance | $20,001,000 | $512,000 | $33,229,000 |
| Repurchase Of Capital Stock | - | $-615,000 | - |
Other
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Issuance Of Debt | $6,000,000 | $0 | - |
| Income Tax Paid Supplemental Data | $371,000 | $244,000 | $209,000 |
| End Cash Position | $5,212,000 | $2,724,000 | $37,339,000 |
| Beginning Cash Position | $2,724,000 | $37,339,000 | $42,370,000 |
| Effect Of Exchange Rate Changes | $26,000 | - | - |
| Changes In Cash | $2,462,000 | $-34,615,000 | $-5,031,000 |
| Net Issuance Payments Of Debt | $6,000,000 | $0 | - |
| Net Long Term Debt Issuance | $6,000,000 | $0 | - |
| Long Term Debt Issuance | $6,000,000 | $0 | - |
| Net Business Purchase And Sale | $1,909,000 | $0 | - |
| Sale Of Business | $1,909,000 | $0 | - |
| Change In Working Capital | $1,130,000 | $1,097,000 | $-954,000 |
| Change In Other Current Liabilities | $-1,641,000 | $-536,000 | - |
| Change In Other Current Assets | $1,429,000 | $288,000 | - |
| Change In Payables And Accrued Expense | $2,599,000 | $-653,000 | $-461,000 |
| Change In Accrued Expense | $2,875,000 | $-646,000 | - |
| Change In Payable | $-276,000 | $-7,000 | $-461,000 |
| Change In Account Payable | $-724,000 | $-472,000 | $-512,000 |
| Change In Tax Payable | $448,000 | $465,000 | - |
| Change In Income Tax Payable | $448,000 | $465,000 | - |
| Change In Prepaid Assets | $-1,491,000 | $2,232,000 | $-1,174,000 |
| Change In Receivables | $234,000 | $-234,000 | $681,000 |
| Changes In Account Receivables | $234,000 | $-234,000 | $681,000 |
| Other Non Cash Items | $9,866,000 | - | - |
| Stock Based Compensation | $1,223,000 | $2,244,000 | $2,684,000 |
| Asset Impairment Charge | $145,000 | $0 | - |
| Depreciation Amortization Depletion | $369,000 | $162,000 | $168,000 |
| Depreciation And Amortization | $369,000 | $162,000 | $168,000 |
| Gain Loss On Investment Securities | $5,854,000 | - | - |
| Net Income From Continuing Operations | $-48,072,000 | $-38,013,000 | $-40,254,000 |
| Common Stock Payments | - | $-615,000 | - |
| Proceeds From Stock Option Exercised | - | - | $101,000 |
| Net Investment Purchase And Sale | - | - | $0 |
| Sale Of Investment | - | - | $0 |
| Net PPE Purchase And Sale | - | - | $-5,000 |
| Purchase Of PPE | - | - | $-5,000 |
| Depreciation | - | - | $168,000 |